SCHEMBL949471

SCHEMBL949471

CC(C)C[Si](Cl)(c1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.33
TAAR1 Q96RJ0 8/20 0.32
SLC6A2 P23975 2/20 0.32
SIGMAR1 Q99720 2/20 0.32
MAOA P21397 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
CYP2A6 P11509 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
ALDH1A1 P00352 1/20 0.31
ESR1 P03372 1/20 0.31
ESR2 Q92731 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
SLC18A2 Q05940 1/20 0.30
CYP2D6 P10635 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12815723 0.87 TACR1 (0.31) ALDH1A1MEN1KMT2ATDP1
SCHEMBL12817878 0.84 TP53 (0.36) CYP2A6ALDH1A1
SCHEMBL1315704 0.82 AOC3 (0.33) AOC3TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL5030059 0.82 AOC3 (0.33) AOC3TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL12815909 0.82 TACR1 (0.35)
SCHEMBL1314169 0.80 ESR1 (0.34) AOC3TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL18662201 0.77 HTR2A (0.41) AOC3TAAR1SLC6A2SLC6A4SLC6A3
SCHEMBL28646155 0.77 AOC3 (0.31) AOC3
SCHEMBL3885758 0.76 MAOA (0.35) AOC3TAAR1SLC6A2SIGMAR1MAOA
SCHEMBL28927447 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020115547-A2 PYRROLO[2,3-D]PYRIMIDIN-2-ONE ANTIMICROBIAL COMPOUNDS BioVersys AG (CH) 2020-06-11 WO disclosed
EP-3601204-A1 SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOALKANE AND (4'-HYDROXYPHENYL)CYCLOALKENE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM FOR ENHANCED MEMORY CONSOLIDATION Marquette University (US) 2020-02-05 EP disclosed
WO-2018183800-A1 SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOALKANE AND (4'-HYDROXYPHENYL)CYCLOALKENE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM FOR ENHANCED MEMORY CONSOLIDATION MARQUETTE UNIVERSITY (US) 2018-10-04 WO disclosed
EP-3194382-A1 PYRAZOLE DERIVATIVES AS SGC STIMULATORS Ironwood Pharmaceuticals, Inc. (US) 2017-07-26 EP disclosed
WO-2016044447-A1 PYRAZOLE DERIVATIVES AS SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2016-03-24 WO disclosed
EP-2691357-A1 METHOD FOR PRODUCING 1-HEXENE Sumitomo Chemical Company Limited (JP) 2014-02-05 EP disclosed
US-20140012056-A1 METHOD FOR PRODUCING 1-HEXENE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-09 US disclosed
WO-2013038153-A1 18F-LABELLED BARBITURATE COMPOUNDS FOR USE AS POSITRON EMISSION IMAGING AGENTS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2013-03-21 WO disclosed
WO-2012133937-A1 METHOD FOR PRODUCING 1-HEXENE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-04 WO disclosed
WO-2012133921-A1 CATALYST FOR OLEFIN OLIGOMERIZATION AND METHOD FOR PRODUCING α-OLEFIN SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-04 WO disclosed
US-5741794-A PLATELET ACTIVATING FACTOR BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-04-21 US disclosed
EP-0620813-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1994-10-26 EP disclosed
EP-0593464-A1 BENZOIC ACID DERIVATIVES and their use as LTB4 inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1994-04-27 EP disclosed
US-5276153-A Antagonist of platelet activating factor for bronchodilation BRITISH BIO-TECHNOLOGY LIMITED (GB) 1994-01-04 US disclosed
WO-1993014069-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-07-22 WO disclosed
EP-0543861-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-06-02 EP disclosed
EP-0593464-A4 BENZOIC ACID DERIVATIVES. SMITHKLINE BEECHAM CORP (US) 1993-02-12 EP disclosed
US-5180723-A Hypertensives, bronchodilators, antiedemic agents BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-01-19 US disclosed
WO-1992003422-A1 BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION BRITISH BIO-TECHNOLOGY LIMITED (GB) 1992-03-05 WO disclosed
WO-1991018601-A1 BENZOIC ACID DERIVATIVES SMITHKLINE BEECHAM CORPORATION (US) 1991-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140012056-A1 METHOD FOR PRODUCING 1-HEXENE AP2A1, AP1M1, ME1 AOC3 166/4885TAAR1 794/4885SLC6A2 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.